Highest-materiality recent filing
Anebulo to voluntarily delist from Nasdaq and deregister SEC; Q2 net loss $2.0M
Board approved voluntary delisting from Nasdaq and SEC deregistration; expects delisting effective Feb 27, 2026.
Board approved voluntary delisting from Nasdaq and deregistration with SEC on Feb 5, 2026; Nasdaq notified Feb 6.
Anebulo completes oversubscribed tender offer, buys 300K shares at $3.50/share
Final count: 4,907,881 shares tendered, oversubscribed.
Anebulo tender offer oversubscribed; 4.9M shares tendered, 300k accepted at $3.50 per share
4,897,188 shares properly tendered (excluding 10,868 by guaranteed delivery).
Anebulo abandons reverse split, launches self-tender for up to 300k shares at $3.50/sh to go private
Abandons reverse stock split (1-for-2,500 to 1-for-7,500) due to cost increase from holders splitting shares to get multiple fractional payments.
Anebulo Pharma Q1 net loss $2.2M; advances IV selonabant Phase 1 study
Net loss of $2.2M ($0.05/sh) in Q1 FY2026, flat vs prior year; operating expenses $2.3M.
Q4 FY2025 net loss of $2.1M ($0.05/shr) vs $1.3M ($0.05/shr) prior year; full-year net loss $8.5M ($0.25/shr) vs $8.2M ($0.32/shr).
Anebulo updates on going private: Board to consider sale, merger, or other alternatives
Received inbound interest from potential financial and strategic partners after announcing going private on July 23, 2025.
Anebulo plans going-private via reverse split; $3.50/share for fractional shares, 91% premium
Reverse stock split ratio range 1-for-2,500 to 1-for-7,500; stockholder vote at special meeting Aug 22, 2025.
Anebulo reports Q3 net loss $1.7M; advancing IV selonabant for pediatric cannabis toxicity
Operating expenses $1.9M in Q3 fiscal 2025 vs $1.7M year ago.
Anebulo regains Nasdaq compliance on private placement share restrictions
Nasdaq confirmed compliance with Listing Rule 5635(b) on April 11, 2025.
Anebulo shareholders approve authorized share increase to 75M and board declassification
Stockholders approved raising authorized common shares from 50M to 75M at the April 4, 2025 Annual Meeting.
Authorized common stock increased from 50M to 75M shares; stock incentive plan pool raised by 2.5M to 6.15M shares.
Anebulo faces Nasdaq delisting risk after change of control; enters lock-up with 22NW
Nasdaq determined that Dec 2024 private placement caused a change of control, violating Listing Rule 5635(b); company received notice Feb 20, 2025.
Net loss for Q2 FY2025 (Dec 31, 2024) was $2.5M, or $0.09 per share, compared to $2.7M ($0.11) in prior year.
Anebulo sets 2025 annual meeting for April 4; stockholder proposals due Feb 22
Annual Meeting scheduled for April 4, 2025; location to be in proxy materials.
Raised $15M gross from sale of 15.2M shares at $0.99/share; change of control as director Aron English now owns >50% of common stock.
Anebulo Pharma Q1 net loss narrows to $2.2M; awarded $1.9M NIDA grant for selonabant
Net loss of $2.2M ($0.08/sh) vs $2.5M ($0.10/sh) in prior year quarter.
Anebulo updates corporate presentation; no specific changes disclosed in filing extract
Company furnished an updated Corporate Presentation as Exhibit 99.1 under Item 7.01.
Q4 FY2024 net loss $1.3M ($0.05/sh) vs $2.5M ($0.10/sh) in Q4 FY2023.
Anebulo awarded up to $1.9M NIDA grant for IV selonabant development
Grant from NIDA/NIH up to ~$1.9M over two years for IV selonabant as emergency treatment for acute cannabis-induced toxicities.
Anebulo adopts new non-employee director equity compensation policy
Initial grant of option to purchase 50,000 shares, vesting monthly over 3 years.
Anebulo Q3 FY2024 net loss $0.06/shr vs $0.11; pivots to pediatric cannabis antidote
Net loss $1.7M ($0.06/shr), narrower than $2.8M ($0.11) a year ago; operating expenses $1.7M (down 41%).
Anebulo Pharma Q2 FY2024 net loss narrows to $2.7M; cash $6.6M; advancing selonabant
Net loss $2.7M ($0.11/sh) vs $3.8M ($0.15/sh) in Q2 FY2023; operating expenses $2.8M.
Anebulo stockholders approve increase in authorized shares and re-elect directors
Stockholders re-elected Jason M. Aryeh and Bimal Shah as Class III directors with ~23.1M votes for each.
Anebulo Q1 FY2024 net loss $2.5M; FDA positive on Phase 3 path for ANEB-001
Net loss of $2.5M ($0.10/sh) vs $2.6M ($0.11/sh) in prior year quarter; operating expenses $2.5M.
Anebulo terminates CEO Simon Allen, appoints Richie Cunningham as new CEO
Simon Allen terminated without cause as CEO; resigned from board effective Oct 5, 2023.
Anebulo appoints part-time CFO Daniel George replacing Sandra Gardiner effective Sept 28
Daniel George appointed part-time CFO, principal financial and accounting officer; replaces Sandra A. Gardiner.
Anebulo reports FY2023 net loss of $11.7M; cash $11.2M; FDA supports Phase 3
Net loss for FY2023 was $11.7M ($0.47 per share) vs $6.8M ($0.29) in FY2022.
Anebulo Pharmaceuticals' Acting CFO resigns as advisory agreement with Potrero terminated
Potrero Hill Advisors terminated Master Services Agreement with Anebulo effective Sept 28, 2023.
Net loss $2.8M ($0.11 per share) vs $1.9M ($0.08) in Q3 FY2022.
Anebulo furnishes Part B final data charts for ANEB-001 Phase 2 trial, consistent with prior results
Exhibit 99.1 contains graphical charts of Part B final data from Phase 2 trial of ANEB-001 for acute cannabinoid intoxication.
Anebulo reports positive Phase 2 results for ANEB-001 reversing THC effects
Low 10 mg dose of ANEB-001 given 1 hour after THC rapidly reversed psychotropic effects (VAS feeling high p<0.0001).
Anebulo appoints Sandra A. Gardiner as Acting CFO via Potrero Hill Advisors agreement
Sandra A. Gardiner appointed Acting CFO, principal financial and accounting officer effective March 2, 2023.
Anebulo reports Q2 fiscal 2023 net loss of $3.8M; Phase 2 trial completed for ANEB-001
Net loss of $3.8M ($0.15 per share) vs $1.1M ($0.05) in Q2 fiscal 2022.
Anebulo: Phase 2 data show ANEB-001 reduces THC effects; cash $16M runway into 2024
Preliminary data: single 10 mg ANEB-001 reversed key psychotropic effects of 30 mg THC, including feeling high and body sway.
Anebulo Pharma Q1 FY2023 net loss $2.6M ($0.11/sh); positive ANEB-001 Phase 2 data
Net loss $2.6M vs $1.6M YoY; diluted EPS ($0.11) vs ($0.07).
Anebulo shareholders elect three Class II directors, ratify auditor at 2022 annual meeting
Directors elected: Nat Calloway (15,985,642 for, 7,456 withheld), Areta Kupchyk (15,982,304 for, 10,794 withheld), Kenneth Lin (15,982,304 for, 10,794 withheld).
Anebulo Pharmaceuticals adopts amended bylaws to comply with universal proxy rules
Board of Directors adopted Amended and Restated Bylaws on October 11, 2022.
Anebulo raises $6.6M in private placement of common shares and warrants
Sold 2,264,650 units at $2.935 each for aggregate proceeds of ~$6.6 million; each unit consists of one share and one warrant.
Anebulo reports positive interim Phase 2 data for ANEB-001 in acute cannabinoid intoxication
Part B: 21mg THC challenge; 10mg or 30mg ANEB-001 significantly reduced VAS feeling high (p<0.001), improved alertness (p<0.01), and reduced body sway (p<0.01) vs placebo.
Anebulo reports Q4 net loss $0.10/share; cash $14.5M; positive Phase 2 data for ANEB-001
Q4 fiscal 2022 net loss of $2.3M ($0.10 per share), vs $29.1M ($1.59) in prior year quarter.
Anebulo's ANEB-001 meets primary endpoint in Phase 2 ACI trial (p<0.0001)
Primary endpoint VAS 'Feeling High' met (p<0.0001) for both 50mg and 100mg ANEB-001 vs placebo.
Anebulo appoints Kenneth Cundy as CSO; $350K salary, options, milestone vesting
Dr. Cundy appointed CSO effective May 20, 2022; base salary $350,000, annual bonus up to 30%.
Anebulo reports Q3 FY2022 net loss $1.9M; Phase 2 trial fully enrolled
Net loss of $1.9M ($0.08/share) for Q3 FY2022 vs $0.6M ($0.68/share) year ago.
Dosed more than half of the 60 planned subjects in Part A of Phase 2 trial for ANEB-001 at CHDR in Netherlands.
Anebulo reports Q2 FY2022 net loss $1.1M; starts Phase 2 trial for ANEB-001; appoints new CEO
Net loss $1.1M ($0.05/sh) vs $0.3M ($0.03/sh) in Q2 FY2021; operating expenses $1.1M.
Anebulo Pharmaceuticals names Simon Allen CEO effective Feb 1, 2022; Dr. Schneeberger resigns
Simon Allen appointed CEO and director, effective Feb 1, 2022; succeeds Daniel Schneeberger.
First patient dosed in Phase 2 proof-of-concept study evaluating ANEB-001 for acute cannabinoid intoxication.
Stockholders elected three Class I directors: Joseph Lawler, Daniel Schneebeger, Aron English.
On October 6, 2023, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), terminated without cause the employment of Simon Allen, the Company’s Chief Executive Officer.
the Company appointed Bimal Shah as a member of the Board and as a member of the Audit Committee and the Compensation Committee of the Board.
the Board appointed Richard (Richie) Anthony Cunningham as the Company’s Chief Executive Officer and as a member of the Board.
On September 26, 2023, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), appointed Daniel George as the Company’s part-time Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, effective September 28, 2023, replacing Sandra A. Gardiner in such capacities.
On September 26, 2023, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), appointed Daniel George as the Company’s part-time Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, effective September 28, 2023, replacing Sandra A. Gardiner in such capacities.
On August 29, 2023, in connection with the termination of the Master Services Agreement, Sandra A. Gardiner notified the Company of her resignation as the Company’s Acting Chief Financial Officer, including as the Company’s principal financial officer and principal accounting officer, effective as of the Termination Date.
On March 2, 2023, the Company appointed Sandra A. Gardiner as the Company’s Acting Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, replacing Rex Merchant in such capacities.
replacing Rex Merchant in such capacities.
On May 24, 2022, Anebulo Pharmaceuticals, Inc. announced that Kenneth C. Cundy has been appointed as the Chief Scientific Officer of our company effective May 20, 2022.
On January 3, 2022, Simon Allen was appointed to be our Chief Executive Officer and elected a member of our Board of Directors, both to be effective on February 1, 2022.
Daniel Schneeberger, M.D. resigned such positions in order to bring in Mr. Allen.
Daniel Schneeberger, M.D. resigned such positions in order to bring in Mr. Allen.
Max materiality 0.90 · Median 0.60 · Most common event other_material